Overexpression of membrane-bound fas ligand (CD95L) exacerbates autoimmune disease and renal pathology in pristane-induced lupus

Journal of Immunology

Volumn 191, Issue 5, 2013, Pages 2104-2114

  Bossaller, Lukas ^a   Rathinam, Vijay A K ^a   Bonegio, Ramon ^b   Chiang, Ping I ^a   Busto, Patricia ^a   Wespiser, Adam R ^a   Caffrey, Daniel R ^a   Li, Quan Zhen ^c   Mohan, Chandra ^c   Fitzgerald, Katherine A ^a   Latz, Eicke ^a,d,e   Marshak Rothstein, Ann ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF BONN   (Germany)

^e GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; FAS LIGAND; PRISTANE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; EXUDATE; GENE DELETION; GENE OVEREXPRESSION; IMMUNOPATHOGENESIS; LOSS OF FUNCTION MUTATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROPHAGE; MEMBRANE BINDING; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEINURIA; SPLEEN CELL; WILD TYPE;

ANIMALS; APOPTOSIS; BALB 3T3 CELLS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FLOW CYTOMETRY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TERPENES; TRANSCRIPTOME;

EID: 84883407551     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300341     Document Type: Article

References (69)

1. Watanabe-Fukunaga, R., C. I. Brannan, N. G. Copeland, N. A. Jenkins, and S. Nagata. 1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356: 314-317.
2. Nagata, S., and P. Golstein. 1995. The Fas death factor. Science 267: 1449-1456.
3. Ju, S. T., D. J. Panka, H. Cui, R. Ettinger, M. el-Khatib, D. H. Sherr, B. Z. Stanger, and A. Marshak-Rothstein. 1995. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373: 444-448.
4. Hohlbaum, A. M., M. S. Gregory, S. T. Ju, and A. Marshak-Rothstein. 2001. Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors. J. Immunol. 167: 6217-6224.
5. Stranges, P. B., J. Watson, C. J. Cooper, C. M. Choisy-Rossi, A. C. Stonebraker, R. A. Beighton, H. Hartig, J. P. Sundberg, S. Servick, G. Kaufmann, et al. 2007. Elimination of antigen-presenting cells and autoreactive T cells by Fas contributes to prevention of autoimmunity. Immunity 26: 629-641.
6. Miwa, K., M. Asano, R. Horai, Y. Iwakura, S. Nagata, and T. Suda. 1998. Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand. Nat. Med. 4: 1287-1292.
7. Strasser, A., P. J. Jost, and S. Nagata. 2009. The many roles of FAS receptor signaling in the immune system. Immunity 30: 180-192.
8. Vargo-Gogola, T., H. C. Crawford, B. Fingleton, and L. M. Matrisian. 2002. Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. Arch. Biochem. Biophys. 408: 155-161.
9. Schulte, M., K. Reiss, M. Lettau, T. Maretzky, A. Ludwig, D. Hartmann, B. de Strooper, O. Janssen, and P. Saftig. 2007. ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death. Cell Death Differ. 14: 1040-1049.
10. Kayagaki, N., A. Kawasaki, T. Ebata, H. Ohmoto, S. Ikeda, S. Inoue, K. Yoshino, K. Okumura, and H. Yagita. 1995. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182: 1777-1783.
11. Schneider, P., N. Holler, J.-L. Bodmer, M. Hahne, K. Frei, A. Fontana, and J. Tschopp. 1998. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187: 1205-1213.
12. Shudo, K., K. Kinoshita, R. Imamura, H. Fan, K. Hasumoto, M. Tanaka, S. Nagata, and T. Suda. 2001. The membrane-bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity. Eur. J. Immunol. 31: 2504-2511.
13. Suda, T., H. Hashimoto, M. Tanaka, T. Ochi, and S. Nagata. 1997. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 186: 2045-2050.
14. Hohlbaum, A. M., S. Moe, and A. Marshak-Rothstein. 2000. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J. Exp. Med. 191: 1209-1220.
15. Gregory, M. S., C. G. Hackett, E. F. Abernathy, K. S. Lee, R. R. Saff, A. M. Hohlbaum, K. S. Moody, M. W. Hobson, A. Jones, P. Kolovou, et al. 2011. Opposing roles for membrane bound and soluble Fas ligand in glaucomaassociated retinal ganglion cell death. PLoS ONE 6: e17659.
16. O' Reilly, L. A., L. Tai, L. Lee, E. A. Kruse, S. Grabow, W. D. Fairlie, N. M. Haynes, D. M. Tarlinton, J. G. Zhang, G. T. Belz, et al. 2009. Membranebound Fas ligand only is essential for Fas-induced apoptosis. Nature 461: 659-663.
17. Griffith, T. S., T. Brunner, S. M. Fletcher, D. R. Green, and T. A. Ferguson. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270: 1189-1192.
18. Ferguson, T. A., and R. S. Apte. 2008. Angiogenesis in eye disease: immunity gained or immunity lost? Semin. Immunopathol. 30: 111-119.
19. Kono, D. H., and A. N. Theofilopoulos. 2006. Genetics of SLE in mice. Springer Semin. Immunopathol. 28: 83-96.
20. Satoh, M., J. P. Weintraub, H. Yoshida, V. M. Shaheen, H. B. Richards, M. Shaw, and W. H. Reeves. 2000. Fas and Fas ligand mutations inhibit autoantibody production in pristane-induced lupus. J. Immunol. 165: 1036-1043.
21. Wu, J., C. Metz, X. Xu, R. Abe, A. W. Gibson, J. C. Edberg, J. Cooke, F. Xie, G. S. Cooper, and R. P. Kimberly. 2003. A novel polymorphic CAAT/enhancerbinding protein β element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J. Immunol. 170: 132-138.
22. Saff, R. R., E. S. Spanjaard, A. M. Hohlbaum, and A. Marshak-Rothstein. 2004. Activation-induced cell death limits effector function of CD4 tumor-specific T cells. J. Immunol. 172: 6598-6606.
23. Li, Q. Z., J. Zhou, A. E. Wandstrat, F. Carr-Johnson, V. Branch, D. R. Karp, C. Mohan, E. K. Wakeland, and N. J. Olsen. 2007. Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes. Clin. Exp. Immunol. 147: 60-70.
24. -/- mouse models of systemic lupus erythematosus. J. Immunol. 184: 796-806.
25. Lee, P. Y., Y. Kumagai, Y. Li, O. Takeuchi, H. Yoshida, J. Weinstein, E. S. Kellner, D. Nacionales, T. Barker, K. Kelly-Scumpia, et al. 2008. TLR7-dependent and FcγR-independent production of type I interferon in experimental mouse lupus. J. Exp. Med. 205: 2995-3006.
26. Lee, P. Y., Y. Kumagai, Y. Xu, Y. Li, T. Barker, C. Liu, E. S. Sobel, O. Takeuchi, S. Akira, M. Satoh, and W. H. Reeves. 2011. IL-1α modulates neutrophil recruitment in chronic inflammation induced by hydrocarbon oil. J. Immunol. 186: 1747-1754.
27. Croker, B. A., R. S. Lewis, J. J. Babon, J. D. Mintern, D. E. Jenne, D. Metcalf, J. G. Zhang, L. H. Cengia, J. A. O'Donnell, and A. W. Roberts. 2011. Neutrophils require SHP1 to regulate IL-1β production and prevent inflammatory skin disease. J. Immunol. 186: 1131-1139.
28. + T cells responding to a bacterial superantigen. J. Immunol. 154: 4302-4308.
29. Liles, W. C., P. A. Kiener, J. A. Ledbetter, A. Aruffo, and S. J. Klebanoff. 1996. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J. Exp. Med. 184: 429-440.
30. Sharma, S., R. B. DeOliveira, P. Kalantari, P. Parroche, N. Goutagny, Z. Jiang, J. Chan, D. C. Bartholomeu, F. Lauw, J. P. Hall, et al. 2011. Innate immune recognition of an AT-rich stem-loop DNA motif in the Plasmodium falciparum genome. Immunity 35: 194-207.
31. Gariglio, M., M. De Andrea, M. Lembo, M. Ravotto, C. Zappador, G. Valente, and S. Landolfo. 1998. The murine homolog of the HIN 200 family, Ifi 204, is constitutively expressed in myeloid cells and selectively induced in the monocyte/macrophage lineage. J. Leukoc. Biol. 64: 608-614.
32. Bossaller, L., P. I. Chiang, C. Schmidt-Lauber, S. Ganesan, W. J. Kaiser, V. A. Rathinam, E. S. Mocarski, D. Subramanian, D. R. Green, N. Silverman, et al. 2012. Cutting edge: FAS (CD95) mediates noncanonical IL-1β and IL-18 maturation via caspase-8 in an RIP3-independent manner. J. Immunol. 189: 5508-5512.
33. Lee, P. Y., J. S. Weinstein, D. C. Nacionales, P. O. Scumpia, Y. Li, E. Butfiloski, N. van Rooijen, L. Moldawer, M. Satoh, and W. H. Reeves. 2008. A novel type I IFN-producing cell subset in murine lupus. J. Immunol. 180: 5101-5108.
34. Nacionales, D. C., K. M. Kelly, P. Y. Lee, H. Zhuang, Y. Li, J. S. Weinstein, E. Sobel, Y. Kuroda, J. Akaogi, M. Satoh, and W. H. Reeves. 2006. Type I interferon production by tertiary lymphoid tissue developing in response to 2,6,10,14-tetramethyl-pentadecane (pristane). Am. J. Pathol. 168: 1227-1240.
35. Saitoh, T., T. Satoh, N. Yamamoto, S. Uematsu, O. Takeuchi, T. Kawai, and S. Akira. 2011. Antiviral protein viperin promotes Toll-like receptor 7- and Tolllike receptor 9-mediated type I interferon production in plasmacytoid dendritic cells. Immunity 34: 352-363.
36. Yin, Y., X. Wu, G. Shan, and X. Zhang. 2012. Diagnostic value of serum anti-C1q antibodies in patients with lupus nephritis: a meta-analysis. Lupus 21: 1088-1097.
37. Eckert, M., I. Wittmann, M. Röllinghoff, A. Gessner, and M. Schnare. 2006. Endotoxin-induced expression of murine bactericidal permeability/ increasing protein is mediated exclusively by Toll/IL-1 receptor domain-containing adaptor inducing IFN-β-dependent pathways. J. Immunol. 176: 522-528.
38. Reeves,W. H., P. Y. Lee, J. S.Weinstein, M. Satoh, and L. Lu. 2009. Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol. 30: 455-464.
39. Sverdrup, B., H. Källberg, C. Bengtsson, I. Lundberg, L. Padyukov, L. Alfredsson, and L. Klareskog; Epidemiological Investigation of Rheumatoid Arthritis Study Group. 2005. Association between occupational exposure to mineral oil and rheumatoid arthritis: results from the Swedish EIRA case-control study. Arthritis Res. Ther. 7: R1296-R1303.
40. Dahlgren, J., H. Takhar, P. Anderson-Mahoney, J. Kotlerman, J. Tarr, and R. Warshaw. 2007. Cluster of systemic lupus erythematosus (SLE) associated with an oil field waste site: A cross sectional study. Environ. Health 6: 8.
41. Calvani, N., R. Caricchio, M. Tucci, E. S. Sobel, F. Silvestris, P. Tartaglia, and H. B. Richards. 2005. Induction of apoptosis by the hydrocarbon oil pristane: implications for pristane-induced lupus. J. Immunol. 175: 4777-4782.
42. Tinazzi, E., A. Puccetti, R. Gerli, A. Rigo, P. Migliorini, S. Simeoni, R. Beri, M. Dolcino, N. Martinelli, R. Corrocher, and C. Lunardi. 2009. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment. Int. Immunol. 21: 237-243.
43. Fisher, G. H., F. J. Rosenberg, S. E. Straus, J. K. Dale, L. A. Middleton, A. Y. Lin, W. Strober, M. J. Lenardo, and J. M. Puck. 1995. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81: 935-946.
44. Rensing-Ehl, A., S. Hess, H. W. Ziegler-Heitbrock, G. Riethmüller, and H. Engelmann. 1995. Fas/Apo-1 activates nuclear factor kappa B and induces interleukin-6 production. J. Inflamm. 45: 161-174.
45. Schaub, F. J., D. K. Han, W. C. Liles, L. D. Adams, S. A. Coats, R. K. Ramachandran, R. A. Seifert, S. M. Schwartz, and D. F. Bowen-Pope. 2000. Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells. Nat. Med. 6: 790-796.
46. Richards, H. B., M. Satoh, M. Shaw, C. Libert, V. Poli, and W. H. Reeves. 1998. Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J. Exp. Med. 188: 985-990.
47. Schmitt, E., H. U. Beuscher, C. Huels, P. Monteyne, R. van Brandwijk, J. van Snick, and E. Ruede. 1991. IL-1 serves as a secondary signal for IL-9 expression. J. Immunol. 147: 3848-3854.
48. Jäger, A., V. Dardalhon, R. A. Sobel, E. Bettelli, and V. K. Kuchroo. 2009. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J. Immunol. 183: 7169-7177.
49. Vink, A., G. Warnier, F. Brombacher, and J. C. Renauld. 1999. Interleukin 9-induced in vivo expansion of the B-1 lymphocyte population. J. Exp. Med. 189: 1413-1423.
50. Wilhelm, C., J. E. Turner, J. Van Snick, and B. Stockinger. 2012. The many lives of IL-9: a question of survival? Nat. Immunol. 13: 637-641.
51. Chung, Y., S. H. Chang, G. J. Martinez, X. O. Yang, R. Nurieva, H. S. Kang, L. Ma, S. S. Watowich, A. M. Jetten, Q. Tian, and C. Dong. 2009. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 30: 576-587.
52. Hsu, H. C., P. Yang, J. Wang, Q. Wu, R. Myers, J. Chen, J. Yi, T. Guentert, A. Tousson, A. L. Stanus, et al. 2008. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat. Immunol. 9: 166-175.
53. Shah, K., W. W. Lee, S. H. Lee, S. H. Kim, S. W. Kang, J. Craft, and I. Kang. 2010. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res. Ther. 12: R53.
54. Okamura, H., H. Tsutsi, T. Komatsu, M. Yutsudo, A. Hakura, T. Tanimoto, K. Torigoe, T. Okura, Y. Nukada, K. Hattori, et al. 1995. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 378: 88-91.
55. Nakanishi, K., T. Yoshimoto, H. Tsutsui, and H. Okamura. 2001. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 12: 53-72.
56. Amerio, P., A. Frezzolini, D. Abeni, P. Teofoli, C. R. Girardelli, O. De Pità, and P. Puddu. 2002. Increased IL-18 in patients with systemic lupus erythematosus: relations with Th-1, Th-2, pro-inflammatory cytokines and disease activity. IL-18 is a marker of disease activity but does not correlate with pro-inflammatory cytokines. Clin. Exp. Rheumatol. 20: 535-538.
57. Esfandiari, E., I. B. McInnes, G. Lindop, F. P. Huang, M. Field, M. Komai-Koma, X.Wei, and F. Y. Liew. 2001. A proinflammatory role of IL-18 in the development of spontaneous autoimmune disease. J. Immunol. 167: 5338-5347.
58. Tsutsui, H., K. Nakanishi, K. Matsui, K. Higashino, H. Okamura, Y. Miyazawa, and K. Kaneda. 1996. IFN-γ-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J. Immunol. 157: 3967-3973.
59. Altemeier, W. A., X. Zhu, W. R. Berrington, J. M. Harlan, and W. C. Liles. 2007. Fas (CD95) induces macrophage proinflammatory chemokine production via a MyD88-dependent, caspase-independent pathway. J. Leukoc. Biol. 82: 721-728.
60. Fitzgerald, K. A. 2011. The interferon inducible gene: viperin. J. Interferon Cytokine Res. 31: 131-135.
61. Qiu, L. Q., P. Cresswell, and K. C. Chin. 2009. Viperin is required for optimal Th2 responses and T-cell receptor-mediated activation of NF-κB and AP-1. Blood 113: 3520-3529.
62. Nacionales, D. C., K. M. Kelly-Scumpia, P. Y. Lee, J. S. Weinstein, R. Lyons, E. Sobel, M. Satoh, and W. H. Reeves. 2007. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum. 56: 3770-3783.
63. Kaplan, M. J. 2011. Neutrophils in the pathogenesis and manifestations of SLE. Nat. Rev. Rheumatol. 7: 691-699.
64. Garcia-Romo, G. S., S. Caielli, B. Vega, J. Connolly, F. Allantaz, Z. Xu, M. Punaro, J. Baisch, C. Guiducci, R. L. Coffman, et al. 2011. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 3: 73ra20.
65. Petty, R. E., D. W. Hunt, and A. M. Rosenberg. 1986. Antibodies to type IV collagen in rheumatic diseases. J. Rheumatol. 13: 246-253.
66. Keogh, A. M., L. S. Ibels, D. H. Allen, J. P. Isbister, and M. C. Kennedy. 1984. Exacerbation of Goodpasture's syndrome after inadvertent exposure to hydrocarbon fumes. Br. Med. J. (Clin. Res. Ed.) 288: 188.
67. lpr mice with autoimmune lupus nephritis. Arthritis Rheum. 46: 3083-3095.
68. 1 mice with monoclonal antibody against Fas ligand. J. Autoimmun. 14: 151-157.
69. González-Cuadrado, S., C. Lorz, R. García del Moral, F. O'Valle, C. Alonso, F. Ramiro, A. Ortiz-González, J. Egido, and A. Ortiz. 1997. Agonistic anti-Fas antibodies induce glomerular cell apoptosis in mice in vivo. Kidney Int. 51: 1739-1746.